These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 12208215)

  • 1. Positive inotropy for acute heart failure complicating myocardial infarction.
    Coats AJ
    Eur Heart J; 2002 Sep; 23(18):1405-6. PubMed ID: 12208215
    [No Abstract]   [Full Text] [Related]  

  • 2. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN).
    Moiseyev VS; Põder P; Andrejevs N; Ruda MY; Golikov AP; Lazebnik LB; Kobalava ZD; Lehtonen LA; Laine T; Nieminen MS; Lie KI;
    Eur Heart J; 2002 Sep; 23(18):1422-32. PubMed ID: 12208222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heart failure update.
    Gomes UC; Cleland JG
    Eur J Heart Fail; 1999 Aug; 1(3):301-2. PubMed ID: 10935680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Levosimendan in heart failure after surgical repair of cardiac rupture.
    Torrado H; Ventura JL; Ruiz-Majoral A; Farrero E; Rodriguez-Castro D; Carrio ML; Miralles A
    Minerva Cardioangiol; 2009 Feb; 57(1):137-8. PubMed ID: 19202525
    [No Abstract]   [Full Text] [Related]  

  • 5. Levosimendan in patients with decompensated heart failure.
    Rosa EM; Osório AP; Scopel L
    Arq Bras Cardiol; 2008 Aug; 91(2):119. PubMed ID: 18709265
    [No Abstract]   [Full Text] [Related]  

  • 6. BELIEF: believe it or not.
    Beck-da-Silva L; Fuchs FD
    Arq Bras Cardiol; 2008 Aug; 91(2):119-21. PubMed ID: 18709264
    [No Abstract]   [Full Text] [Related]  

  • 7. Can we believe in levosimendan?
    Follath F
    Arq Bras Cardiol; 2008 Mar; 90(3):146-7. PubMed ID: 18392391
    [No Abstract]   [Full Text] [Related]  

  • 8. Improved survival with simendan after experimental myocardial infarction in rats.
    Levijoki J; Pollesello P; Kaheinen P; Haikala H
    Eur J Pharmacol; 2001 May; 419(2-3):243-8. PubMed ID: 11426847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacotherapeutic approaches for decompensated heart failure: a role for the calcium sensitiser, levosimendan?
    Greenberg B; Borghi C; Perrone S
    Eur J Heart Fail; 2003 Jan; 5(1):13-21. PubMed ID: 12559210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug discovery and development for acute heart failure drugs: are expectations too high?
    Pollesello P
    Int J Cardiol; 2014 Mar; 172(1):11-3. PubMed ID: 24472177
    [No Abstract]   [Full Text] [Related]  

  • 11. Levosimendan use in several scenarios of acute heart failure.
    Tavares M; Andrade AC; Mebazaa A
    Arq Bras Cardiol; 2008 Mar; 90(3):211-5. PubMed ID: 18392402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Levosimendan: a new option in acute septic cardiac failure?
    Powell BP; De Keulenaer B
    Emerg Med Australas; 2007 Apr; 19(2):177; author reply 177-8. PubMed ID: 17448109
    [No Abstract]   [Full Text] [Related]  

  • 13. Advances in positive inotropic therapy: levosimendan.
    Frishman WH
    Crit Care Med; 2003 Sep; 31(9):2408-9. PubMed ID: 14501979
    [No Abstract]   [Full Text] [Related]  

  • 14. Levosimendan: a new era for inodilator therapy for heart failure?
    Cleland JG; McGowan J
    Curr Opin Cardiol; 2002 May; 17(3):257-65. PubMed ID: 12015475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Levosimendan beyond inotropy and acute heart failure: Evidence of pleiotropic effects on the heart and other organs: An expert panel position paper.
    Farmakis D; Alvarez J; Gal TB; Brito D; Fedele F; Fonseca C; Gordon AC; Gotsman I; Grossini E; Guarracino F; Harjola VP; Hellman Y; Heunks L; Ivancan V; Karavidas A; Kivikko M; Lomivorotov V; Longrois D; Masip J; Metra M; Morelli A; Nikolaou M; Papp Z; Parkhomenko A; Poelzl G; Pollesello P; Ravn HB; Rex S; Riha H; Ricksten SE; Schwinger RHG; Vrtovec B; Yilmaz MB; Zielinska M; Parissis J
    Int J Cardiol; 2016 Nov; 222():303-312. PubMed ID: 27498374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Successful use of levosimendan in a patient with cardiogenic shock complicating acute myocardial infarction].
    Mustapha F; Moufida H; Nedia B; Anis L; Iheb L; Habib H
    Tunis Med; 2005 Oct; 83(10):635-7. PubMed ID: 16370217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Levosimendan is superior to enoximone in refractory cardiogenic shock complicating acute myocardial infarction.
    Beute J
    Crit Care Med; 2009 Sep; 37(9):2678; author reply 2678-9. PubMed ID: 19687655
    [No Abstract]   [Full Text] [Related]  

  • 18. Safety and efficacy of levosimendan in patients with cardiac amyloidosis.
    Aimo A; Rapezzi C; Arzilli C; Vergaro G; Emdin M
    Eur J Intern Med; 2020 Oct; 80():114-116. PubMed ID: 32631802
    [No Abstract]   [Full Text] [Related]  

  • 19. New positive inotropic agents in the treatment of left ventricular dysfunction.
    De Luca L; Proietti P; Palombaro GL; Battagliese A; Celotto A; Bucciarelli Ducci C; Fedele F
    Ital Heart J; 2004 Jun; 5 Suppl 6():63S-67S. PubMed ID: 15185917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pre-operative use of levosimendan in two patients with severe aortic stenosis and left ventricular dysfunction.
    Prior DL; Flaim BD; MacIsaac AI; Yii MY
    Heart Lung Circ; 2006 Feb; 15(1):56-8. PubMed ID: 16473793
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.